Email
Print
Carbapenem Market By Type (Meropenem, Doripenem, Imipenem, Tebipenem, Others), By Indication (Bacterial Meningitis, Acute Pelvic Infections, Respiratory Tract Infections, Intra-abdominal Infections, Urinary Tract Infections, Others), By Distribution Channel (Retail Pharmacies, Online Pharmacies, Hospital Pharmacies) - Forecast(2024 - 2030)
Carbapenem Market Overview:
The global Carbapenem Market is estimated to surpass the $5,876.8 Million
mark by 2030 growing at an estimated CAGR of more than 4.6% during the forecast
period 2023 to 2030. The carbapenem market is a significant segment within the global antibiotics market. Carbapenems are broad-spectrum antibiotics used to treat serious infections caused by multidrug-resistant bacteria. They are highly effective against a wide range of gram-positive and gram-negative bacteria.
The market for carbapenems has been growing steadily due to the increasing prevalence of drug-resistant infections, particularly in hospital settings. The rising incidence of healthcare-associated infections and the need for effective treatment options have also contributed to the market growth.
North America and Europe have traditionally been the largest markets for carbapenems, driven by advanced healthcare infrastructure, high awareness about antimicrobial resistance, and robust research and development activities. However, the Asia Pacific region is
expected to witness significant growth rate of 6.5% during the forecast period
2023 to 2030, due to the increasing healthcare expenditure, growing population,
and rising awareness about infectious diseases. According to Australian Institute of
Health and Welfare, in 2020–21, there were more than 324,000 hospitalisations
for infectious diseases, of which 94% were for non-notifiable diseases.
Market Snapshot:
Carbapenem Market - Report Coverage:
The “Carbapenem Market Report - Forecast (2023-2030)” by IndustryARC, covers an in-depth analysis of the following segments in the smart toys market.
Carbapenem Market - Top Trends:
Increasing prevalence of drug-resistant infections: The rise of multidrug-resistant bacteria, including those resistant to commonly used antibiotics, has fueled the demand for carbapenems. These drugs are often considered as a last resort in the treatment of serious infections when other antibiotics have failed.
Growing awareness about antimicrobial resistance: There has been an increased emphasis on combating antimicrobial resistance globally. Governments, healthcare organizations, and regulatory bodies have been working to raise awareness about the responsible use of antibiotics, including carbapenems, to reduce the emergence of resistant strains.
Expansion of applications: Carbapenems have traditionally been used in hospitals for treating severe infections. However, there has been an expansion of their use in other healthcare settings, such as long-term care facilities and outpatient settings, as well as for specific indications, including complicated urinary tract infections, intra-abdominal infections, and pneumonia.
Development of novel carbapenem formulations: Pharmaceutical companies continue to invest in research and development to develop new carbapenem formulations with improved efficacy, safety, and pharmacokinetic properties. This includes the development of extended-release formulations and combination therapies to enhance their therapeutic potential.
Strategic collaborations and partnerships: Companies in the carbapenem market are increasingly forming collaborations and partnerships to strengthen their product portfolios and expand their market reach. This includes collaborations between pharmaceutical companies, research institutions, and government bodies to support the development of new antibiotics and combat antimicrobial resistance.
The Carbapenem Market - Company Analysis
Merck & Co., Inc.: Merck is a leading pharmaceutical company with a strong presence in the carbapenem market. The company's carbapenem product, Merrem (meropenem), is widely used and has demonstrated efficacy against a range of bacterial infections. Merck focuses on research and development to expand its product portfolio and address the evolving challenges of antimicrobial resistance.
Pfizer Inc.: Pfizer is a global pharmaceutical company involved in the development, manufacturing, and marketing of a wide range of healthcare products, including carbapenem antibiotics. Their carbapenem product, Primaxin (imipenem and cilastatin), is used for the treatment of serious infections. Pfizer invests in research and development to introduce innovative treatments and strengthen its position in the market.
Allergan: Allergan, now part of AbbVie Inc., is a pharmaceutical company known for its expertise in specialized therapeutics. The company offers carbapenem products, including Invanz (ertapenem), which is indicated for various infections. Allergan focuses on developing and commercializing innovative treatments to address unmet medical needs.
AstraZeneca plc: AstraZeneca is a multinational pharmaceutical company involved in the research, development, and commercialization of various therapeutics. The company offers Zinforo (ceftaroline fosamil), which is a broad-spectrum antibiotic used for the treatment of complicated skin and soft tissue infections, including those caused by methicillin-resistant Staphylococcus aureus (MRSA). Although Zinforo is not a carbapenem, it is worth mentioning as an alternative treatment option for certain infections.
Key Market Players:
Product/Service launches, approvals, patents and events, acquisitions, partnerships, and collaborations are key strategies adopted by players in the Incinerator Market Report. The top 10 companies in this industry are listed below:
- Merck & Co., Inc.
- Pfizer Inc.
- AbbVie Inc.
- AstraZeneca plc
- Gilead Sciences
- GlaxoSmithKline plc
- Shionogi & Co., Ltd.
- Sun Pharmaceutical Industries Ltd
- Menarini Group
- Kopran Limited
Scope of Report:
For more Lifesciences and Healthcare Market reports, please click here
1. Carbapenem Market - Overview
1.1. Definitions and Scope
2. Smart Toys Market - Executive Summary
3. Carbapenem Market - Comparative Analysis
3.1. Company Benchmarking - Key Companies
3.2. Global Financial Analysis - Key Companies
3.3. Market Share Analysis - Key Companies
3.4. Patent Analysis
3.5. Pricing Analysis
4. Carbapenem Market - Start-up Companies Scenario (Premium)
4.1. Key Start-up Company Analysis by
4.1.1. Investment
4.1.2. Revenue
4.1.3. Venture Capital and Funding Scenario
5. Carbapenem Market – Market Entry Scenario Premium (Premium)
5.1. Regulatory Framework Overview
5.2. New Business and Ease of Doing Business Index
5.3. Case Studies of Successful Ventures
6. Carbapenem Market - Forces
6.1. Market Drivers
6.2. Market Constraints
6.3. Market Challenges
6.4. Porter's Five Force Model
6.4.1. Bargaining Power of Suppliers
6.4.2. Bargaining Powers of Customers
6.4.3. Threat of New Entrants
6.4.4. Rivalry Among Existing Players
6.4.5. Threat of Substitutes
7. Carbapenem Market – Strategic Analysis
7.1. Value Chain Analysis
7.2. Opportunities Analysis
7.3. Market Life Cycle
8. Carbapenem Market – By Type
8.1. Meropenem
8.1.1. Market Trends by Region
8.1.2. Market Share & Forecast by Region
8.2. Doripenem
8.2.1. Market Trends by Region
8.2.2. Market Share & Forecast by Region
8.3. Imipenem
8.3.1. Market Trends by Region
8.3.2. Market Share & Forecast by Region
8.4. Tebipenem
8.4.1 Market Trends by Region
8.4.2 Market Share & Forecast by Region
9 Carbapenem Market – By Indication
9.1. Bacterial Meningitis
9.1.1. Market Trends by Region
9.1.2. Market Share & Forecast by Region
9.2. Acute Pelvic Infections
9.2.1. Market Trends by Region
9.2.2 Market Share & Forecast by Region
9.3. Respiratory Tract Infections
9.3.1. Market Trends by Region
9.3.2. Market Share & Forecast by Region
9.4. Intra-abdominal Infections
9.4.1. Market Trends by Region
9.4.2. Market Share & Forecast by Region
9.5. Urinary Tract Infections
9.5.1. Market Trends by Region
9.5.2. Market Share & Forecast by Region
10 Carbapenem Market – By Distribution Channel
10.1 Retail Pharmacies
10.1.1 Market Trends by Region
10.1.2 Market Share & Forecast by Region
10.2 Online Pharmacies
10.2.1 Market Trends by Region
10.2.2 Market Share & Forecast by Region
10.3 Hospital Pharmacies
10.3.1 Market Trends by Region
10.3.2 Market Share & Forecast by Region
11 Carbapenem Market – by Geography (Market Size – $Million/$Billion)
11.1 North America
11.1.1 The U.S.
11.1.2 Canada
11.2 Europe
11.2.1 UK
11.2.2 Germany
11.2.3 France
11.2.4 Italy
11.2.5 Spain
11.2.6 Russia
11.2.7 Rest of Europe
11.3 Asia-Pacific
11.3.1 China
11.3.2 India
11.3.3 Japan
11.3.4 South Korea
11.3.5 Australia & New Zealand
11.3.6 Rest of Asia-Pacific
11.4 South America
11.4.1 Brazil
11.4.2 Argentina
11.4.3 Chile
11.4.4 Colombia
11.4.5 Rest of South America
11.5 Rest of the World
11.5.1 Middle East
11.5.2 Africa
12 Carbapenem Market – Entropy
13 Carbapenem Market – Industry/Segment Competition Landscape Premium
13.1 Market Share Analysis
13.1.1 Market Share by Product Type – Key Companies
13.1.2 Market Share by Region – Key Companies
13.1.3 Market Share by Country – Key Companies
13.2 Competition Matrix
13.3 Best Practices for Companies
14 Carbapenem Market – Key Company List by Country Premium Premium
15 Carbapenem Market - Company Analysis
15.1 Pfizer Inc.
15.2 Savior Lifetec
15.3 Sumitomo Dainippon Pharma Co., Ltd.
15.4 Merck & Co., Inc.
15.5 Gland Pharma Limited
15.6 Aurobindo Pharma Ltd
15.7 Daewoong Pharmaceutical Co.,Ltd,
15.8 Iterum Therapeutics plc
15.9 ACS Dobfar S.p.A
15.10 Amneal Pharmaceuticals LLC
15.11 Apotex, Inc.
15.12 Aurobindo Pharma Ltd.
15.13 Daewoong Pharmaceutical Co., Ltd.
15.14 Gland Pharma Ltd.
15.15 Fedora Pharmaceuticals, Inc.
15.16 Iterum Therapeutics plc
15.17 Jeil Pharmaceutical Co., Ltd.
15.18 Johnson & Johnson Pharmaceuticals
15.19 Meiji Seika Pharma Co., Ltd.
15.20 Merck & Co., Inc.SSS
• "Financials to the Private Companies would be provided on best-effort basis."
Connect with our experts to get customized reports that best suit your requirements. Our
reports include global-level data, niche markets and competitive landscape.
The Carbapenem Market is projected to grow at 4.6 % CAGR during the forecast period 2023-2030.
Carbapenem Market size is projected to reach $5876.8 Million by 2030.
The leading players in the Carbapenem Market are Amneal Pharmaceuticals LLC, Apotex, Inc., Aurobindo Pharma Ltd., Daewoong Pharmaceutical Co., Ltd., Gland Pharma Ltd., Fedora Pharmaceuticals, Inc, Iterum Therapeutics plc, Jeil Pharmaceutical Co., Ltd., Johnson & Johnson Pharmaceuticals, Meiji Seika Pharma Co., Ltd., Merck & Co., Inc.SSS.